INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Leveraging Technology in Phase I Clinical Trials

Ana Palijan, PhD

Ana Palijan, PhD

Director, Early Phase and Translational Research

Author picture
In the ever-evolving landscape of clinical research, Phase I studies are becoming increasingly complex. We’re proud to announce that two of our trailblazing colleagues, Ana Palijan, Director, Early Phase and Translational Research, and Éric Hardy, Senior Director, Biometrics, have contributed to a groundbreaking white paper that explores these complexities. Their expert analysis highlights the challenges and opportunities within Phase I trials, offering valuable insights for industry professionals. Key Highlights:
  • In-depth Analysis: Explore the intricacies of Phase I studies, providing a comprehensive overview of the current landscape.
  • Expert Opinions: Gain insights from leading professionals who are at the forefront of clinical research.
  • Future Trends: Understand the emerging trends and how they might impact the future of Phase I trials.
This white paper is a must-read for anyone involved in clinical research. Whether you’re a seasoned professional or new to the field, the insights provided will enhance your understanding and approach to Phase I studies. Dive into this white paper now!

Common Questions About Phase I Clinical Trial Technology

Get answers to frequently asked questions about technology in Phase I research, then download the full white paper for more details.
How is the design and execution of Phase I clinical trials changing?
Phase I trials have evolved beyond basic safety and toxicology assessments and now often incorporate more endpoints, biomarkers, and exploratory objectives. Influences from later-phase development, combined with new therapeutic modalities and regulatory expectations, have increased protocol complexity, site counts, and data volume. While these changes can add scientific value, they also demand more intentional design to avoid over-engineering early-phase studies.
Balancing speed and data volume starts with clearly defining the purpose of the Phase I study and identifying which data are essential for decision-making. Collecting excessive data can slow timelines due to added monitoring, cleaning, and transformation requirements. Sponsors that justify each variable with a clear business or scientific rationale are better positioned to move efficiently toward database lock and Phase II readiness.
Best practices for effective management of data complexity include:
  • Simplifying protocols
  • Limiting endpoints to those that matter most
  • Aligning study design with downstream needs
  • Engaging cross-functional teams early
  • Avoiding unnecessary variables
  • Embedding data standards into study builds
These steps help reduce operational burden, improve data quality, and prevent delays during analysis and closeout.
Electronic Data Capture (EDC) is the most widely used technology in Phase I trials, serving as the foundation for managing increasingly complex datasets. Other commonly used tools include RTSM/IRT for randomization and supply management and ePRO for patient-reported outcomes. While many studies still rely on hybrid approaches, adoption of digital tools continues to grow as trials become more data intensive.
Sponsors should evaluate technology based on study objectives, protocol complexity, budget constraints, and site capabilities. Flexibility is critical, as Phase I trials often require rapid adjustments to data collection and workflows. Selecting systems that support standardization, scalability, and real-time data access can improve efficiency and ease the transition into later-phase development.
Talk to us

Jeff Smith

Chef de la direction
Linkedin

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >